Aclaris Therapeutics, Inc. (ACRS): Free Cash Flow
-$47.22M
Year ended 2025-12-31
-$62.18M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$47.22M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$20.20M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$79.63M | n/m | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | -$68.17M | n/m | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | -$52.44M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$39.09M | n/m | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | -$98.06M | n/m | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | -$102.17M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$55.90M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | -$34.84M | n/m | 2019-03-18, From 2016-01-01 |
| 2015-12-31 | -$20.88M | n/m | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | -$8.05M | n/a | 2017-03-15, From 2014-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$47.22M | n/m |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | -$39.92M | n/m |
| Adagene Inc. (ADAG) | 2025-12-31 | -$15.67M | n/m |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | -$279.92M | n/m |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | -$758.56M | n/m |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | -$38.33M | n/m |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | -$97.98M | n/m |
| Immunome Inc. (IMNM) | 2025-12-31 | -$200.60M | n/m |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | -$82.35M | n/m |
Compare ACRS, BOLT, ADAG, XENE side by side · Screen every company in Pharmaceutical Preparations ↗